Glucagon: Dasiglucagon Bi-hormonal Closed-Loop Pivotal Trial Delayed; Zealand Q2 ’20 Earnings Update
Zealand hosted its Q2 ’20 earnings call and discussed its clinical and commercial activities, including the acceleration of US commercial operations for the potential HypoPal launch in H1 ’21 and the delay in the bi-hormonal pivotal trial initiation which is now expected in early 2021. Below, FENIX provides brief thoughts and insights from the call.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.